ALK-Abelló Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Peter Halling
Chief executive officer
DKK 20.6m
Total compensation
| CEO salary percentage | 38.19% |
| CEO tenure | 3.3yrs |
| CEO ownership | n/a |
| Management average tenure | 5.3yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Narrative Update • Apr 24
ALK B: Future Upside Will Come From Needle Free Anaphylaxis Treatment Adoption
Analysts have nudged their price target for ALK-Abelló to DKK 263.33 from DKK 255, reflecting updated assumptions around slightly adjusted revenue growth, profit margin expectations, and a higher future P/E multiple. What's in the News ALK reported positive topline phase 2 data from the ALLIANCE trial of its once daily sublingual immunotherapy tablet for peanut allergy in patients aged 4 to 65 years, with statistically significant, dose dependent efficacy across multiple tolerated dose and eliciting dose endpoints and a safety profile without treatment related anaphylaxis or serious adverse events (Key Developments).Narrative Update • Apr 09
ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption
Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.Narrative Update • Mar 25
ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption
Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.Narrative Update • Mar 11
ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption
Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).Narrative Update • Feb 25
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins
Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).Narrative Update • Feb 10
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins
Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.Narrative Update • Jan 27
ALK B: Future Returns Will Reflect Upgraded 2025 Outlook And Stable Margin Ambitions
Analysts have kept their price target for ALK-Abelló steady at DKK 214. This reflects unchanged assumptions around discount rate, revenue growth, profit margin and future P/E, and indicates that new research has not materially shifted their valuation view.
New Narrative • Jan 23
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?Analysis Article • Jan 23
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Narrative Update • Jan 12
ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects
Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).Narrative Update • Dec 19
ALK B: Future Returns Will Reflect Upgraded Outlook And Solid Margin Prospects
Analysts have modestly lifted their average price target on ALK-Abelló to DKK 219.33, reflecting steady confidence in the company’s unchanged long term growth, margin, and valuation assumptions despite minimal adjustments to underlying model inputs. What's in the News Upgraded 2025 revenue guidance to 13% to 15% growth in local currencies, from 12% to 14%, supported by stronger demand across all regions and product lines (company guidance).Analysis Article • Dec 08
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
With a price-to-earnings (or "P/E") ratio of 45.8x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...Narrative Update • Dec 05
ALK B: Future Returns Will Reflect China Alliance And Margin Outlook
Analysts have maintained their DKK 219.33 price target for ALK Abelló, reflecting stable expectations for sustained double digit revenue growth, robust profit margins and a premium future P E multiple. What's in the News Upgraded 2025 guidance, with expected revenue growth raised to 13% to 15% in local currencies, supported by higher treatment volumes across allergy immunotherapy and anaphylaxis products, and an improved projected EBIT margin of about 26% (company guidance).Narrative Update • Nov 21
ALK B: Improved Margins and China Partnership Will Drive Steady Outlook
Analysts have raised their price target for ALK-Abelló to DKK 219.33 from DKK 196.00. They cite ongoing improvements in profit margins and a slightly higher projected fair value as the reasons for the adjustment.Analysis Article • Nov 15
ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...Narrative Update • Nov 04
ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities
Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.Analysis Article • Oct 11
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Aug 23
Allergy+ Strategy Will Reach Millions With New Therapies
The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.Analysis Article • Jul 23
ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 44.9x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...Analysis Article • Jun 17
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Narrative • Dec 11
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | DKK 1b |
| Dec 31 2025 | DKK 21m | DKK 8m | DKK 1b |
| Sep 30 2025 | n/a | n/a | DKK 1b |
| Jun 30 2025 | n/a | n/a | DKK 999m |
| Mar 31 2025 | n/a | n/a | DKK 937m |
| Dec 31 2024 | DKK 18m | DKK 7m | DKK 815m |
Compensation vs Market: Peter's total compensation ($USD3.19M) is about average for companies of similar size in the Danish market ($USD2.73M).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Halling (48 yo)
3.3yrs
Tenure
DKK 20,550,000
Compensation
Mr. Peter Halling is President & Chief Executive Officer of ALK-Abelló A/S from 2023 and serves as its Member of Management Board. Mr. Peter Halling served as Chief Executive Officer at Fertin Pharma A/S s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.3yrs | DKK 20.55m | no data | |
| Executive VP | 2.9yrs | DKK 9.60m | no data | |
| Member of Management Board | 14yrs | DKK 13.27m | no data | |
| Senior Project Director | no data | DKK 400.00k | no data | |
| Senior Manager of QA Release & Employee Representative Director | no data | DKK 400.00k | no data | |
| Senior Maintenance Supporter of Process & Production Support & Employee Representative Director | no data | DKK 400.00k | no data | |
| Project Director of Global Clinical Development & Employee-elected Director | no data | DKK 400.00k | no data | |
| VP of Corporate Communications | no data | no data | no data | |
| Executive Vice President of Global People & Organisation | 2.3yrs | no data | no data | |
| Senior Vice President of Research & Development - North America and International Markets | 9.2yrs | no data | no data | |
| Executive Vice President of Product Supply | 7.3yrs | no data | no data | |
| Senior Vice President of Global Research & Drug Discovery | no data | no data | no data |
5.3yrs
Average Tenure
53yo
Average Age
Experienced Management: ALK B's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior Project Director | 15.3yrs | DKK 400.00k | no data | |
| Senior Manager of QA Release & Employee Representative Director | 7.2yrs | DKK 400.00k | no data | |
| Senior Maintenance Supporter of Process & Production Support & Employee Representative Director | 7.2yrs | DKK 400.00k | no data | |
| Project Director of Global Clinical Development & Employee-elected Director | 3.2yrs | DKK 400.00k | no data | |
| Independent Director | 3.2yrs | DKK 540.00k | no data | |
| Vice Chairman of the Board | 12.3yrs | DKK 1.00m | no data | |
| Independent Chairman of the Board | 6.2yrs | DKK 1.45m | no data | |
| Director | 11.2yrs | DKK 540.00k | no data | |
| Independent Director | 5.2yrs | DKK 610.00k | no data | |
| Independent Director | 4.2yrs | DKK 650.00k | no data | |
| Independent Director | 5.2yrs | DKK 550.00k | no data |
6.2yrs
Average Tenure
62yo
Average Age
Experienced Board: ALK B's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 10:34 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALK-Abelló A/S is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ingildsen | DNB Carnegie |